Finding the best prices at pharmacies near you...

Prescription & Medication Blog

At RxSpark we believe prescription drugs and medication should be accessible and affordable for all Americans. In addition to the savings, discounts, and convenience that RxSpark provides, the RxSpark Blog is here to bring you information, news, current events, and important upates on topics that affect healthcare and prescription drugs. Be sure to check back frequently for updates, and if you find any information that is particularly helpful please don't hesitate to share!



'Six out of ten Americans plan to get a flu vaccine in 2017-18'

More than six out of ten (61%) Americans get a flu vaccine each year or plan to get one this year, two percentage points higher than last year, according to a recent survey conducted on behalf of CVS Health. Seniors aged 65 and above were more likely to get immunization than younger people, with 76...

Read More

ALS drug Radicava now available in US pharmacies

A new treatment option for patients with amyotrophic lateral sclerosis (ALS) is now available in US pharmacies for the first time in 22 years. Radicava (edavarone), developed and manufactured by Mitsubishi Tanabe Pharma America, was approved by the US Food and Drug Administration (FDA) in May 2017....

Read More

5 Top Tips for Safe Medication Management

The number of prescriptions filled in the United States has risen from 2.4 billion 1997 to 4.4 billion in 2016, according to figures from Quintiles IMS. With a recent Consumer Reports survey showing more than half of Americans regularly take prescription medication, the need for organized and safe...

Read More

Vyxeos approval a 'welcome therapeutic advance for AML patients'

Vyxeos (daunorubicin and cytarabine) has been approved by the US Food and Drug Administration (FDA). It is the first treatment approved for patients with certain types of high-risk acute myeloid leukemia (AML). The drug, developed by Jazz Pharmaceuticals, is a fixed combination of two chemotherapy...

Read More

HCV treatment with 98% cure rate gets FDA nod

The US Food and Drug Administration (FDA) approved the hepatitis C virus (HCV) treatment Mavyret (glecaprevir, pibrentasvir), granting biopharmaceutical firm AbbVie Breakthrough Therapy Designation and Priority Review for the treatment of GT1 HCV patients not cured with prior direct-acting...

Read More